Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b
- 1 August 2008
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 135 (2), 459-467
- https://doi.org/10.1053/j.gastro.2008.05.031
Abstract
No abstract availableKeywords
Funding Information
- Foundation for Liver Research
- Stichting voor Lever- en Maag-Darm Onderzoek
This publication has 25 references indexed in Scilit:
- Acute liver failure in Spain: Analysis of 267 casesLiver Transplantation, 2007
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialThe Lancet, 2005
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJournal of Viral Hepatitis, 2004
- The long‐term effect of treatment with interferon‐α2a in chronic hepatitis BJournal of Viral Hepatitis, 1998
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Comparing methods of measurement: why plotting difference against standard method is misleadingThe Lancet, 1995
- Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis BAnnals of Internal Medicine, 1993
- Hepatitis B virus deoxyribonucleic acid in liver of chronic carriersGastroenterology, 1987